This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Gendicine" – news · newspapers · books · scholar · JSTOR(June 2018) (Learn how and when to remove this message)
Gendicine
Clinical data
ATC code
None
Legal status
Legal status
In general: ℞ (Prescription only)
Gendicine is a gene therapy medication used to treat patients with head and neck squamous cell carcinoma linked to mutations in the TP53 gene. It consists of recombinant adenovirus engineered to code for p53 protein (rAd-p53) and is manufactured by Shenzhen SiBiono GeneTech.
Gendicine was the first gene therapy product to obtain regulatory approval for clinical use in humans[1] after Chinese State Food and Drug Administration approved it in 2003.[2]
^Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. (February 2018). "The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic". Human Gene Therapy. 29 (2): 160–179. doi:10.1089/hum.2017.218. PMID 29338444.
Gendicine is a gene therapy medication used to treat patients with head and neck squamous cell carcinoma linked to mutations in the TP53 gene. It consists...
trials were conducted, with more than half of them in phase I. In 2003, Gendicine became the first gene therapy to receive regulatory approval. Since that...
a viable cancer treatment option. The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of head and neck squamous...
settings. In 2003, China approved the first gene therapy for clinical use: Gendicine, an adenoviral vector encoding p53. In 2012, the European Union issued...
imatinib 2002 – The State Food and Drug Administration of China approves Gendicine, gene therapy for cancer 2002 – Corporate takeover of Dupont by BMS resulted...
Exagamglogene autotemcel (Casgevy): treatment for sickle cell disease. Gendicine: treatment for head and neck squamous cell carcinoma Idecabtagene vicleucel...
However, cetuximab's efficacy is still under investigation by researchers. Gendicine is a gene therapy that employs an adenovirus to deliver the tumor suppressor...
first gene therapy product to be licensed to treat cancer, Gendicine, is an adenovirus. Gendicine, an adenoviral p53-based gene therapy was approved by the...
a step forward and a step back; first gene therapy drug was approved, Gendicine, which was approved in China for the treatment of certain cancers, but...
Global Information